GVAG
BBIO icon

Great Valley Advisor Group’s BridgeBio Pharma BBIO Stock Holding History

Great Valley Advisor Group’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-6,000
Closed -$281K – 600
2021
Q3 		$281K Hold
6,000
– – 0.02% 480
2021
Q2 		$366K Buy
+6,000
New +$343K 0.03% 413

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Great Valley Advisor Group's BBIO Position: Q4 2021 in Review

Great Valley Advisor Group sold out of BridgeBio Pharma (BBIO) in Q4 2021, closing a stake of 6,000 shares — an estimated $281K sold.

Great Valley Advisor Group first reported a position in BBIO in Q2 2021 and held it in 2 quarters. The position peaked at $366K in Q2 2021. 195 funds tracked by Wall St. Rank hold BBIO as of Q4 2021.

  • Great Valley Advisor Group reported no remaining BridgeBio Pharma position as of Q4 2021 after selling out during the quarter.
  • Great Valley Advisor Group sold 6,000 BridgeBio Pharma shares in Q4 2021, an estimated $281K.
  • Great Valley Advisor Group first reported a position in BridgeBio Pharma in Q2 2021 and held it in 2 quarters.
  • Great Valley Advisor Group's BridgeBio Pharma position peaked at $366K in Q2 2021.
  • 195 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2021.

Based on Great Valley Advisor Group's 13F filing for Q4 2021, filed 10 Feb 2022.